Peptide LibraryResearch statistics
Icatibant research: publications and trials
At a glance
Publications, all years
1,450
Since 1990
Publications in 2026 so far
20
Through November 1, 2026
Human clinical research
14.6%
210 of 1,440 classified
Registered clinical trials
28
ClinicalTrials.gov
Randomized controlled trials
34
Publications reporting an RCT in people
Systematic reviews and meta-analyses
7
Preclinical studies
73.1%
903 animal · 143 in vitro · 6 computational
Records that only mention it
718
Not counted above
Status in the library: FDA-approved. 10 publications are not yet classified by study type.
What to keep in mind
- More than 70% of the indexed publications are animal, cell or computational studies.
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Icatibant publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 1990 | 0 | 1 | 0 | 0 | 1 |
| 1991 | 0 | 5 | 0 | 2 | 7 |
| 1992 | 0 | 38 | 3 | 1 | 42 |
| 1993 | 0 | 44 | 1 | 0 | 45 |
| 1994 | 2 | 64 | 1 | 1 | 68 |
| 1995 | 2 | 79 | 2 | 2 | 85 |
| 1996 | 1 | 90 | 1 | 1 | 93 |
| 1997 | 1 | 73 | 3 | 0 | 77 |
| 1998 | 1 | 71 | 2 | 1 | 75 |
| 1999 | 1 | 81 | 0 | 3 | 85 |
| 2000 | 5 | 67 | 0 | 0 | 72 |
| 2001 | 2 | 49 | 0 | 1 | 52 |
| 2002 | 1 | 31 | 1 | 0 | 33 |
| 2003 | 2 | 36 | 0 | 0 | 38 |
| 2004 | 0 | 34 | 1 | 0 | 35 |
| 2005 | 1 | 28 | 2 | 1 | 32 |
| 2006 | 2 | 36 | 3 | 0 | 41 |
| 2007 | 1 | 23 | 4 | 0 | 28 |
| 2008 | 2 | 21 | 9 | 0 | 32 |
| 2009 | 4 | 23 | 5 | 0 | 32 |
| 2010 | 9 | 12 | 9 | 2 | 32 |
| 2011 | 12 | 15 | 9 | 5 | 41 |
| 2012 | 10 | 17 | 14 | 5 | 46 |
| 2013 | 9 | 18 | 9 | 0 | 36 |
| 2014 | 15 | 10 | 4 | 0 | 29 |
| 2015 | 20 | 10 | 1 | 10 | 41 |
| 2016 | 14 | 13 | 6 | 4 | 37 |
| 2017 | 13 | 10 | 8 | 3 | 34 |
| 2018 | 16 | 8 | 6 | 1 | 31 |
| 2019 | 7 | 12 | 4 | 1 | 24 |
| 2020 | 11 | 5 | 7 | 2 | 25 |
| 2021 | 8 | 4 | 1 | 5 | 18 |
| 2022 | 7 | 5 | 3 | 3 | 18 |
| 2023 | 10 | 8 | 0 | 3 | 21 |
| 2024 | 0 | 3 | 1 | 0 | 4 |
| 2025 | 14 | 4 | 1 | 1 | 20 |
| 2026 (to date) | 7 | 4 | 5 | 4 | 20 |
Study types
| Animal study | 903 |
|---|---|
| In vitro study | 143 |
| Review | 119 |
| Case report | 86 |
| Observational human study | 70 |
| Editorial, letter or other | 46 |
| Randomized controlled trial | 34 |
| Other clinical trial | 20 |
| Not yet classified | 10 |
| Computational study | 6 |
| Systematic review | 6 |
| Guideline or consensus | 5 |
| Meta-analysis | 1 |
| Correction or retraction notice | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Cardiovascular | 891 |
|---|---|
| Immune system | 494 |
| Dermatology | 289 |
| Neurological and mental health | 127 |
| Gastrointestinal | 83 |
| Reproductive and sexual health | 76 |
| Musculoskeletal | 63 |
| Antimicrobial and infectious disease | 51 |
| Endocrinology | 51 |
| Metabolic health | 51 |
| Tissue repair | 49 |
| Oncology | 22 |
Registered clinical trials
3 of 21 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 23 · Active, not recruiting: 2 · Terminated: 2 · Withdrawn: 1
Phase not applicable: 4 · Phase 1: 2 · Phase 2: 7 · Phase 2 / Phase 3: 2 · Phase 3: 9 · Phase 4: 4
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Effect of icatibant on angiotensin-converting enzyme inhibitor-induced angioedema: A meta-analysis of randomized controlled trials.
Journal of clinical pharmacy and therapeutics · July 9, 2019 · Meta-analysis · cited 33 times · open access
PMID 31290163 · DOI 10.1111/jcpt.12997 · Reviews and meta-analyses
- Icatibant for acute hereditary angioedema attacks in pediatric patients: A systematized review.
Allergy and asthma proceedings · July 1, 2026 · Systematic review · cited 2 times
PMID 42343494 · DOI 10.2500/aap.2026.47.260042 · Reviews and meta-analyses
- Diverse Trial Designs, Populations, and Outcomes: A Systematic Literature Review of Trials for the Treatment of Hereditary Angioedema Attacks.
Advances in therapy · June 18, 2026 · Systematic review · cited 0 times · open access
PMID 42313271 · DOI 10.1007/s12325-026-03656-7 · Reviews and meta-analyses
- Efficacy of Treatment of Non-hereditary Angioedema.
Clinical reviews in allergy & immunology · June 1, 2018 · Systematic review · cited 27 times · open access
PMID 27672078 · DOI 10.1007/s12016-016-8585-0 · Reviews and meta-analyses
- Pharmacotherapy for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: A Systematic Review.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · November 7, 2017 · Systematic review · cited 18 times
PMID 29112487 · DOI 10.1177/0194599817737974 · Reviews and meta-analyses
- Novel Therapies for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: A Systematic Review of Current Evidence.
The Journal of emergency medicine · September 20, 2017 · Systematic review · cited 34 times
PMID 28939396 · DOI 10.1016/j.jemermed.2017.05.037 · Reviews and meta-analyses
- [Administration of conestat alfa, human C1 esterase inhibitor and icatibant in the treatment of acute angioedema attacks in adults with hereditary angioedema due to C1 esterase inhibitor deficiency. Treatment comparison based on systematic review results].
Pneumonologia i alergologia polska · January 1, 2013 · Systematic review · cited 3 times · open access
PMID 23420425 · DOI 10.5603/arm.27510 · Reviews and meta-analyses
- Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure.
Circulation. Heart failure · April 24, 2026 · Randomized controlled trial · cited 1 times · open access
PMID 42028604 · DOI 10.1161/circheartfailure.125.014117 · Human clinical research
- Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant.
Pathogens (Basel, Switzerland) · May 27, 2025 · Randomized controlled trial · cited 1 times · open access
PMID 40559541 · DOI 10.3390/pathogens14060533 · Human clinical research
- A single-blind, randomized, crossover study on the efficacy of icatibant for sweating-induced dermal pain (icatibant for sweating-induced dermal pain).
Medicine · June 1, 2023 · Randomized controlled trial · cited 2 times · open access
PMID 37335648 · DOI 10.1097/md.0000000000033971 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies.
British journal of pharmacology · March 1, 1991 · Animal study · cited 830 times · open access
PMID 1364852 · DOI 10.1111/j.1476-5381.1991.tb12249.x · Animal studies
- Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
Pharmacological reviews · March 1, 1995 · Review · cited 650 times
PMID 7784479 · DOI 10.1016/s0031-6997(25)06820-6 · Reviews and meta-analyses
- Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies.
British journal of pharmacology · March 1, 1991 · Animal study · cited 613 times · open access
PMID 1364851 · DOI 10.1111/j.1476-5381.1991.tb12248.x · Animal studies
- Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.
The Journal of clinical investigation · April 1, 1997 · Animal study · cited 603 times · open access
PMID 9109437 · DOI 10.1172/jci119360 · Animal studies
- Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
The New England journal of medicine · August 1, 2010 · Randomized controlled trial · cited 564 times · open access
PMID 20818888 · DOI 10.1056/nejmoa0906393 · Human clinical research
Latest publications
- Development and validation of an RP-HPLC method for the quantification of impurities of icatibant injection in finished formulations-identification and characterization of its impurities via LC-HRMS.
European journal of mass spectrometry (Chichester, England) · September 30, 2026 · Editorial, letter or other · cited 0 times
PMID 42813886 · DOI 10.1177/14690667261489100 · Commentary and other
- Universal pipeline for high-resolution GPCR structure determination.
Nature structural & molecular biology · August 28, 2026 · In vitro study · cited 0 times
PMID 42665663 · DOI 10.1038/s41594-026-01869-6 · In vitro studies
- Real-World Safety and Effectiveness of Icatibant in Patients With Hereditary Angioedema (HAE): Post-Marketing Surveillance in Japan.
The Journal of dermatology · August 21, 2026 · Observational human study · cited 0 times · open access
PMID 42630033 · DOI 10.1111/1346-8138.70447 · Human clinical research
- Chronic Spontaneous Urticaria with Biochemical C1 Inhibitor Deficiency: A Case Report of Suspected Overlap with Hereditary Angioedema.
Clinical, cosmetic and investigational dermatology · August 5, 2026 · Case report · cited 0 times · open access
PMID 42572754 · DOI 10.2147/ccid.s634574 · Human clinical research
- [Current and future therapies for bradykinin-mediated angioedema].
Dermatologie (Heidelberg, Germany) · August 4, 2026 · Review · cited 0 times
PMID 42550203 · DOI 10.1007/s00105-026-05754-7 · Reviews and meta-analyses
- Overactivated bradykinin-B2 receptor promotes type a aortic dissection by inducing endothelial dysfunction: Therapeutic effect of icatibant.
Life sciences · July 7, 2026 · Animal study · cited 1 times · open access
PMID 42413717 · DOI 10.1016/j.lfs.2026.124572 · Animal studies
- Icatibant for acute hereditary angioedema attacks in pediatric patients: A systematized review.
Allergy and asthma proceedings · July 1, 2026 · Systematic review · cited 2 times
PMID 42343494 · DOI 10.2500/aap.2026.47.260042 · Reviews and meta-analyses
- Diverse Trial Designs, Populations, and Outcomes: A Systematic Literature Review of Trials for the Treatment of Hereditary Angioedema Attacks.
Advances in therapy · June 18, 2026 · Systematic review · cited 0 times · open access
PMID 42313271 · DOI 10.1007/s12325-026-03656-7 · Reviews and meta-analyses
- Could bradykinin pathway inhibition change the course of severe hantavirus disease?
Immunology letters · June 6, 2026 · Editorial, letter or other · cited 0 times · open access
PMID 42251906 · DOI 10.1016/j.imlet.2026.107201 · Commentary and other
- First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · May 30, 2026 · Case report · cited 6 times
PMID 42219034 · DOI 10.1016/j.cmi.2026.05.047 · Human clinical research
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Firazyr; HOE-140; Icatibant; JE-049
((TITLE_ABS:"Firazyr" OR CHEM:"Firazyr") OR (TITLE_ABS:"HOE-140" OR CHEM:"HOE-140" OR TITLE_ABS:"HOE140" OR CHEM:"HOE140") OR (TITLE_ABS:"Icatibant" OR CHEM:"Icatibant") OR (TITLE_ABS:"JE-049" OR CHEM:"JE-049" OR TITLE_ABS:"JE049" OR CHEM:"JE049")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 2). Icatibant research statistics (Version weekly-2026-11-01) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/icatibant